PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma
JCO Precision Oncology · 2026
DOI: 10.1200/po-25-00741 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Princy Gupta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Class I Phosphatidylinositol 3-Kinases, Adenocarcinoma, Mutation. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Approximately one in three patients with appendiceal cancer (AC) is diagnosed before age 50 years. Early-onset appendiceal cancer (EOAC) exhibits distinct clinicopathologic and demographic features compared with late-onset disease, suggesting potential biological differences. However, the molecular differences remain poorly understood. This study aims to compare EOAC and late-onset AC (LOAC, ≥50 years) mutational profiles and evaluate their impact on overall survival (OS). METHODS A retrospective analysis was conducted using the Memorial Sloan Kettering—Metastatic Events and Tropisms database. Patients were stratified by age at the time of surgery into EOAC and LOAC groups. Logistic regression was used to assess differences in mutational profiles between these two groups. Findings were validated using data from the American Association for Cancer Research Genomics Evidence Neoplasia Information Exchange project. Kaplan-Meier survival analysis and multivariable Cox proportional hazard models were used to evaluate associations with survival. RESULTS The study included 200 patients with appendiceal adenocarcinoma (median age: 55 years, IQR, 47-68), of whom 70 (35%) had EOAC and 130 (65%) had LOAC. Patients with EOAC had higher odds of harboring PIK3CA mutations compared with LOAC (17.1% v 7.7%; odd ratio, 2.65; P = .04), which was consistent when combined with the GENIE data set (12.3% v 5.9%; P < .01). PIK3CA mutations were exclusively observed in patients with metastatic disease (11.8%) and were more common in adenocarcinoma not otherwise specified (NOS) than mucinous tumors (63.6% v 36.4%; P = .04). In multivariable analysis, PIK3CA mutations were independently associated with worse OS (hazard ratio, 2.62 [95% CI, 1.32 to 5.20]; P < .01). CONCLUSION PIK3CA mutations are more common in EOAC and independently associated with worse OS. These findings suggest incorporating PIK3C A mutation status into prognostic assessments and warrant further investigation of PIK3CA inhibitors as a potential therapeutic strategy for appendiceal adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Yale School of Medicine, New Haven, CT.
- Department of Medicine, University of Louisville, Louisville, KY.
- Department of Medical Oncology, Yale School of Medicine, New Haven, CT.
- Section of Hematology/Oncology, Department of Internal Medicine, University of Chicago, Chicago, IL.
ORCID-Profile: Princy Gupta, Rushabh Gujarathi, Lu Qiao, Elizabeth L Godfrey, Kurt S Schultz, Samuel D Butensky, Justin M Bader, Raghav Sundar, Michael Cecchini, Ardaman Shergill, Kiran K Turaga
Zitieren
APA
Gupta, P., Gujarathi, R., Qiao, L., Godfrey, E. L., Schultz, K. S., Butensky, S. D., Bader, J. M., Sundar, R., Cecchini, M., Shergill, A., Sheltzer, J. M., & Turaga, K. K. (2026). PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology. https://doi.org/10.1200/po-25-00741
Vancouver
Gupta P, Gujarathi R, Qiao L, Godfrey EL, Schultz KS, Butensky SD, et al. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology. 2026. doi:10.1200/po-25-00741
BibTeX
@article{Gupta2026,
author = {Gupta, Princy and Gujarathi, Rushabh and Qiao, Lu and Godfrey, Elizabeth L and Schultz, Kurt S and Butensky, Samuel D and Bader, Justin M and Sundar, Raghav and Cecchini, Michael and Shergill, Ardaman and Sheltzer, Jason M and Turaga, Kiran K},
title = {PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma},
journal = {JCO Precision Oncology},
year = {2026},
doi = {10.1200/po-25-00741}
}
EUVIMED